4.3 Article

CFTR: New insights into structure and function and implications for modulation by small molecules

期刊

JOURNAL OF CYSTIC FIBROSIS
卷 19, 期 -, 页码 S19-S24

出版社

ELSEVIER
DOI: 10.1016/j.jcf.2019.10.021

关键词

Membrane protein; ABC-transporter; Mutations; F508del; Therapy; Clinical drugs; Cystic fibrosis

资金

  1. Dutch Cystic Fibrosis Foundation, NCFS
  2. Netherlands Organization for Scientific Research (NWO) [731.017.420]
  3. Cystic Fibrosis Foundation Therapeutics (CFTR 3D Structure Consortium)
  4. French Association Vaincre La Mucoviscidose
  5. GENCI-[CINES] [2018-A0040707206, 2019-A0060707206]
  6. National Institutes of Health [NIHR01DK55835]
  7. Cystic Fibrosis Foundation
  8. Agence Nationale pour la Recherche
  9. Programme Hospitalier de Recherche Clinique
  10. Cystic Fibrosis Foundation Therapeutics grant [SHEPPA14XX0]
  11. Cystic Fibrosis Trust [SRC005/SRC011]
  12. Medical Research Council [MR/S00274X/1]
  13. MRC [MR/S00274X/1] Funding Source: UKRI

向作者/读者索取更多资源

Structural biology and functional studies are a powerful combination to elucidate fundamental knowledge about the cystic fibrosis transmembrane conductance regulator (CFTR). Here, we discuss the latest findings, including how clinically-approved drugs restore function to mutant CFTR, leading to better clinical outcomes for people with cystic fibrosis (CF). Despite the prospect of regulatory approval of a CFTR-targeting therapy for most CF mutations, strenuous efforts are still needed to fully comprehend CFTR structure-and-function for the development of better drugs to enable people with CF to live full and active lives. (C) 2019 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据